Board of Directors

Viviane Monges has worked in several business sectors. She served as Chief Financial Officer for the Business Excellence division of Nestlé. She previously spent nearly 20 years directing the financial transactions of three pharmaceutical companies. She served as the Chief Financial Officer of the group Galderma S.A., a multinational company specializing in dermatology. She was Chief Financial Officer of the EMEA region and then world Chief Financial Officer for the OTC division at Novartis. At Wyeth Pharmaceuticals/Pfizer, she held the position of Chief Financial Officer of the Global Pharma Business unit. She also worked for Agence France-Presse (AFP) from 1990 to 1995.

Karl Rotthier is CEO of EUROAPI. With nearly three decades spent in senior management positions, he also brings to his role strong API (Active Pharmaceutical Ingredients) business experience.

Karl has a strong track record in carve-out and spin-off operations. At EUROAPI, he’s put together a committed management team that reflects the DNA of an efficient company: agility, and the ability to unlock its growth potential.

His international career has included positions in Europe and further afield, such as in Singapore. Karl started his career as a lawyer in Belgium and worked for BASF in Belgium and Germany leading, amongst others, the Performance Chemicals business unit of BASF in Ludwigshafen. He then joined DSM and became CEO of DSM Sinochem Pharmaceuticals. More recently, he was CEO of Centrient Pharmaceuticals.

Karl holds master’s degrees in Law from the University of Antwerp (Belgium) and the University of Southampton (UK), and an MBA from Vlerick Business School‎ (Belgium).

Married and a father of two, Karl is a football, skiing and golf fan, and enjoys travel, art and music.

Elizabeth Bastoni is an experienced Board Chair and executive with expertise in human resources, governance, strategy, risk and talent management. She is currently Chair of the Board of Directors of Limead, as well as member of the Board of Directors of Jeronimo Martins and BIC. Elizabeth began her career in international taxation at KPMG in Europe. She then held several executive positions with international groups such as The Coca-Cola Company, Carlson or Thalès.

Emmanuel Blin is the founder and CEO of Tech Care for All (TC4A), a social impact company aiming to accelerate digital health in Africa and Asia created in 2017. Previously, he spent 20 years in the pharmaceutical industry. He is a former member of the Executive Committee of Bristol-Myers Squibb, where he was Chief Strategy Officer and Co-Commercialization Director, after a series of assignments leading national and regional operations in Europe, Asia and the Americas. Mr Blin is President of Aignostics, a Berlin-based company specialising in artificial intelligence in oncology. He is a graduate of ESSEC in Paris and has completed the INSEAD-CEDEP general management programme.

Jean-Christophe Dantonel, appointed by EPIC Bpifrance, acting on behalf of the French State under the French Tech Sovereignty Convention.

Jean-Christophe Dantonel is Director of the Health and Biotechnology program at the General Secretariat for Investment.
Trained at the Ecole Normale Supérieure de Lyon, Jean-Christophe Dantonel obtained his doctorate summa cum laude at the University of Strasbourg in 1999. He joined the Institut National de la Santé et de la Recherche Médicale (Inserm) in 2001, to pursue a scientific career devoted to cancer proliferation. His work has been published in several prestigious scientific journals such as Nature or Molecular Cell.
After a Master of Business Administration at the Institut d'études politiques de Paris, he joined, in 2007, the cabinet of the Minister in charge of Higher Education and Research as Advisor for life sciences and biotechnologies.
In 2010, he joined the founding team of the General Secretariat for Investment to implement the Health axis of the Future Investment Program. In 12 years, more than 400 projects in the health and biology sector have been selected and funded for more than €4 billion. During the Covid crisis, he was assigned by the Prime Minister to lead the negotiations for pre-orders of Covid vaccines.

Cécile Dussart is Vice President, Head of Global Operations of Galderma a Global Specialty pharma company and leader in the Dermatology field. Cécile builds and deploys the strategic road map for Operations driven by Galderma’s transformation program, as well as ensuring a professional and safe culture. She joined Galderma in 2005 as Human Resources Director for Industrial Operations, later becoming Plant Director at the Alby-sur-Chéran production facility in France in 2008. Prior to her roles at Galderma, Cécile was at Roche for more than eight years, where she held positions as Global Brand Manager and then Human Resources Business Partner. She began her career as a Brand Manager at Sanofi in 1990. Cécile studied pharmacy at the University of Paris XI and holds a master’s degree in marketing from ESCP Europe.

Claire Giraut is member of the board and Chair of the Development and Innovation Committee of Julius Baer. She was Member of the Board and Chair of the Audit Committee at DBV Technologies. Claire Giraut has held responsibilities in finance for most of her professional career. She was Chief Financial Officer and IS Officer at BioMérieux (2013-2018), Chief Financial Officer of Europcar Group (2011-2012) and of Ipsen (2003-2011) where she managed the company’s IPO. She began her career by holding various positions, particularly in finance, within the Sanders group. Claire is an agronomy engineer and is a graduate of the Institut National Agronomique in Paris.

Before becoming Chief Financial Officer of the Consumer Health Business (CHC) within the Sanofi group, Adeline Le Franc held various positions within Sanofi in areas such as market studies, international pricing, R&D control, commercial control, strategic planning and financial management of industrial business. Through these experiences, Adeline Le Franc acquired in-depth expertise in the pharmaceutical industry: an understanding of the production chain and the regulatory context, knowledge of the market and the global competitive environment, strategic approaches and project management.

Guillaume Mortelier is a graduate of the Ecole Polytechnique and the Ecole Nationale des Ponts et Chaussées.

Guillaume Mortelier began his career in 2003 at Bain & Company in Paris and San Francisco where he led business development missions in Europe and North America. Between 2007 and 2012, he made equity investments in French SMEs within the Astorg Partners fund and then in companies abroad (mainly in the Mediterranean and China) within Proparco.
In September 2012, Guillaume Mortelier joined CDC Entreprises, a constituent entity of Bpifrance, where he was appointed Director of Development and then Director of Strategy and Development in 2014. In December 2017, he became a member of the Mid & Large Cap Management Committee, in charge of creating and managing the International Build-up Fund.
Guillaume Mortelier was appointed Executive Director in charge of Support on August 1, 2018.

Mattias Perjos is currently President and Chief Executive Officer of Getinge, a listed company on the Stockholm Stock Exchange, which he joined in 2017. He previously held the CEO position at Coesia IPS Division and Coesia International (2012-2017). Prior to that, Mattias Perjos was CEO of Flexlink (2006-2016) and held other leading roles within the group which he joined in 1998. A Swedish citizen, Mattias Perjos holds a Master of Science in Industrial Engineering and Management.

Rodolfo Savitzky is Chief Financial Officer and member of the Executive Board of SoftwareONE. 

After serving as Finance Director at Procter & Gamble for the Beverage Division in Europe and then for the Beauty Care Division in Latin America, he joined Novartis in 2002 in the Pharmaceutical Division, first as Head of Finance for the Ophthalmic Business Unit and then as Head of Business Planning and Analysis followed by Head of Strategic Planning and Analysis for the Pharmaceutical Division. He was appointed CFO for Novartis Animal Health in 2006.  Rodolfo joined Lonza in 2015 where he became Chief Financial Officer and member of the Executive Board in 2016.  He was also a Non-Executive Director and Chairman of the Audit Committee of Unilabs in 2021.

Rodolfo Savitzky holds a bachelor’s degree in Industrial and Systems Engineering from the Monterrey Institute of Technology (ITESM) in Mexico, as well as an MBA from the University of Chicago (Booth School of Business) in the United States. 

Marie-Isabelle Penet is currently Global Senior Process Manager at EUROAPI and has a deep knowledge of process engineering.

She began her career at the Centre National de la Recherche Scientifique (CNRS-French National Centre for Scientific Research) before moving to Altran as an engineer. She then became laboratory head at Rhône-Poulenc before taking roles of increasing responsibilities at Sanofi.

Marie-Isabelle Penet is an engineer in Chemical Engineering by training (ENSIC school) and holds a PhD in Fluid Mechanic. She is also certified in project economic assessment and as such a member of the Société Française pour l'avancement du Management de Projet (French Society for the Advancement of Project Management). She is a member of the board of the Advanced Process Engineering commission of the Société Française de Génie des Procédés (SFGP-French Society of Process Engineering).

Kevin Rodier is currently the HSE QT correspondent at the “120” workshop in EUROAPI Vertolaye (Puy-de-Dôme), a site where he has 16 years' seniority.

After a year spent in the "Operational Excellence" department, he returned to the "Production" department. Kevin Rodier began his career as a production technician before becoming a supervisor in various workshops.

He holds a Brevet de Technicien Supérieur (BTS) in chemistry.